SOPHiA GENETICS SA Initial Statement of Beneficial Ownership
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu filed an initial ownership report showing direct holdings of 174,224 ordinary shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SOPHiA GENETICS SA Chief Medical Officer Philippe Menu filed an initial ownership report showing direct holdings of 174,224 ordinary shares. This figure includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit grants that vest over time, subject to continued service. He also reports several share option awards over ordinary shares with various exercise prices and expirations between 2030 and 2035, providing additional potential equity exposure if exercised in the future.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Share Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (5)
- F1. Includes 115,002 ordinary shares issuable upon settlement of four restricted stock unit ("RSU") grants. Each RSU represents a contingent right to receive one ordinary share of the Issuer, vesting subject to the Reporting Person's continued service with the Issuer, as follows: (i) 2,704 ordinary shares from a May 18, 2022 grant vesting in equal monthly installments through May 18, 2026; (ii) 37,833 ordinary shares from an April 3, 2023 grant vesting in equal quarterly installments through April 3, 2027; (iii) 32,027 ordinary shares from an April 2, 2024 grant vesting in equal quarterly installments through April 2, 2028; and (iv) 42,438 ordinary shares from an April 2, 2025 grant, with 50% vesting on April 2, 2026 and the remainder vesting in equal quarterly installments through April 2, 2027.
- F2. The share options are fully vested and exercisable.
- F3. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 3, 2024, and then in equal monthly installments through April 3, 2027.
- F4. The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2025, and then in equal monthly installments through April 2, 2028.
- F5. The share option vests and becomes exercisable as to 50% of the ordinary shares on April 2, 2026, and then in equal monthly installments through April 2, 2027.
AI-generated analysis. How Rhea-AI works. Not financial advice.
